Stock Research: Mayne Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Mayne Pharma

ASX:MYX AU000000MYX0
6
  • Value
    39
  • Growth
    36
  • Safety
    Safety
    28
  • Combined
    12
  • Sentiment
    20
  • 360° View
    360° View
    6
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Mayne Pharma Group Limited is a specialty pharmaceutical company. It operates in Women’s Health, Dermatology, and International segments and distributes products like NEXTSTELLIS and ANNOVERA. The company operates in the United States and Australia. In the last fiscal year, the company had a market cap of $267 million, profits of $151 million, and revenue of $264 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 6 (better than 6% compared with alternatives), overall professional sentiment and financial characteristics for the stock Mayne Pharma are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with all four indicators below average for Mayne Pharma. The consolidated Value Rank has a low rank of 28 which means that the share price of Mayne Pharma is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 72% of alternative stocks in the same industry. The consolidated Growth Rank also has a low rank of 36, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is lower than for 36% of competitors in the same industry. The consolidated Safety Rank has a riskier rank of 39, which means that the company has a riskier financing structure than 61% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a low rank of 20, which means that professional investors are more pessimistic about the stock than for 80% of alternative investment opportunities. ...read more

more
Index
ASX 300
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
28 40 54 89
Growth
36 84 75 49
Safety
Safety
39 33 53 24
Sentiment
20 40 86 20
360° View
360° View
6 47 92 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
40 60 22 57
Opinions Change
50 50 100 50
Pro Holdings
n/a 1 78 24
Market Pulse
69 69 70 25
Sentiment
20 40 86 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
28 40 54 89
Growth
36 84 75 49
Safety Safety
39 33 53 24
Combined
12 55 71 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
1 86 86 24
Price vs. Earnings (P/E)
81 82 87 93
Price vs. Book (P/B)
70 59 75 95
Dividend Yield
1 1 1 100
Value
28 40 54 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
40 71 80 93
Profit Growth
30 72 4 1
Capital Growth
8 56 50 71
Stock Returns
92 70 99 31
Growth
36 84 75 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
65 59 65 22
Refinancing
46 58 83 77
Liquidity
1 4 8 8
Safety Safety
39 33 53 24

Similar Stocks

Discover high‑ranked alternatives to Mayne Pharma and broaden your portfolio horizons.

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Shionogi

TSE:4507
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Flight Centre Travel

ASX:FLT
Country: Australia
Industry: Hotels, Resorts & Cruise Lines
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.